Aluminium and iron in humans: Bioaccumulation, pathology, and removal

Rejuvenation Research

Volumn 13, Issue 5, 2010, Pages 589-598

  Peto, Maximus V ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM; DRINKING WATER; IRON; PARATHYROID HORMONE;

ALZHEIMER DISEASE; ARTICLE; BIOACCUMULATION; BREAST CANCER; ENVIRONMENTAL EXPOSURE; GASTROINTESTINAL ABSORPTION; HEALTH HAZARD; HEART DISEASE; HUMAN; INSULIN SENSITIVITY; IRON METABOLISM; KIDNEY INJURY; NEOPLASM; NONHUMAN; OSTEOMALACIA; OXIDATIVE STRESS; PREVALENCE; PRIORITY JOURNAL; WASTE COMPONENT REMOVAL;

ALUMINUM; CHELATING AGENTS; DIET; HUMANS; INTESTINAL ABSORPTION; IRON;

EID: 78650012718     PISSN: 15491684     EISSN: None     Source Type: Journal    
DOI: 10.1089/rej.2009.0995     Document Type: Article

References (121)

1. Kawahara M, Kato M, Kuroda, K. Effects of Al on the neurotoxicity of primary cultured neurons and on the aggregation of beta-amyloid protein. Brain Res Bull 2001; 55:211-217.
2. Rondeau V, Jacqmin-Gadda H, Commenges D, Helmer C, Dartigues JF. Aluminum and silica in drinking water and the risk of Alzheimer's disease or cognitive decline: Findings from 15-year follow-up of the PAQUID cohort. Am J Epidemiol 2009;169:489-496.
3. Walton J. Al in hippocampal neurons from humans with Alzheimer's disease. NeuroToxicology 2006;27:385-394.
4. Takashima A. Does Al Contribute to Alzheimer Disease Directly, Indirectly, or At All? J Alzheimers Dis 2007;11: 431-432.
5. Bharathi, Vasudevaraju P, Govindaraju M, Palanisamy AP, Sambamurti K, Rao KS. Molecular toxicity of aluminium in relation to neurodegeneration. Indian J Med Res 2008;128:545-556.
6. Rodella LF, Ricci F, Borsani E, Stacchiotti A, Foglio E, Favero G, Rezzani R, Mariani C, Bianchi R. Aluminium exposure induces Alzheimer's disease-like histopathologi-cal alterations in mouse brain. Histol Histopathol 2008; 23:433-439.
7. Miu AC, Benga O. Aluminum and Alzheimer's disease: A new look. J Alzheimers Dis 2006;10:179-201.
8. Perl DP, Moalem S. Aluminum and Alzheimer's disease, a personal perspective after 25 years. J Alzheimers Dis 2006; 9(3 Suppl):291-300.
9. McDermott JR, Smith AI, Iqbal K, Wisniewski H M. Brain aluminum in aging and Alzheimer's disease. Neurology 1979;29:809-814.
10. Bjertness E, Candy JM, Torvik A, Ince P, McArthur F, Taylor GA, Johansen SW, Alexander J, Grønnesby JK, Bakketeig LS, Edwardson JA. Content of brain aluminum is not elevated in Alzheimer disease. Alzheimer Dis Assoc Disord 1996;10:171-174.
11. McDermott JR, Smith AI, Iqbal K, Wisniewski HM. Aluminum and Alzheimer's disease. Lancet 1977;2:710-711.
12. Yokel RA. Aluminum chelation principles and recent advances. Coord Chem Rev 2002;228:97-113.
13. Ferretti G, Marchionni C, Bacchetti T, Galeazzi T, Dousset N. Effect of aluminium on lipid peroxidation of human high density lipoproteins. Free Radic Res 2003;37:515-521.
14. Verstraeten SV, Aimo L, Oteiza PI. Aluminium and lead: Molecular mechanisms of brain toxicity. Arch Toxicol 2008; 82:789-802.
15. Bondy S, Guo-Ross S, Pien J. Mechanisms underlying the Al-induced potentiation of the pro-oxidant properties of transition metals. Neurotoxicology 1998;19:65-71.
16. Becaria A, Campbell A, Bondy SC. Aluminum as a toxicant. Toxicol Ind Health 2002;18:309-320.
17. Berthon G. Al speciation in relation to Al bioavailability, metabolism and toxicity. Coord Chem Rev 2002;228: 319-341.
18. Quinlan GJ, Halliwell B, Moorhouse CP, Gutteridge JM. Action of lead(II) and aluminium (III) ions on iron-stimulated lipid peroxidation in liposomes, erythrocytes and rat liver microsomal fractions. Biochim Biophys Acta 1988;962:196-200.
19. Ohyashiki T, Karino T, Suzuki S, Matsui K. Effect of aluminum ion on Fe(2\+)-induced lipid peroxidation in phos-pholipid liposomes under acidic conditions. J Biochem 1996;120:895-900.
20. Donnelly SM, Ali MA, Churchill DN. Bioavailability of iron in hemodialysis patients treated with erythropoietin: evidence for the inhibitory role of aluminum. Am J Kidney Dis 1990;16:447-451.
21. Marouani N, Chahed A, Hédhili A, Hamdaoui MH. Both aluminum and polyphenols in green tea decoction (Camellia sinensis) affect iron status and hematological parameters in rats. Eur J Nutr 2007;46:453-459.
22. Cannata JB, Gómez Alonso C, Fernández Menéndez MJ, Fernández Soto I, McGregor S, Menéndez-Fraga P, Brock JH. Iron uptake in aluminium overload: In vivo and in vitro studies. Nephrol Dial Transplant 1991;6:637-642.
23. Hurrell RF, Reddy M, Cook JD. Inhibition of non-haem iron absorption in man by polyphenolic-containing beverages. Br J Nutr 1999;81:289-295.
24. Zijp IM, Korver O, Tijburg LB. Effect of tea and other dietary factors on iron absorption. Crit Rev Food Sci Nutr 2000;40:371-398.
25. Nelson M, Poulter J. Impact of tea drinking on iron status in the UK: A review. J Hum Nutr Diet 2004;17:43-54.
26. Flaten TP. Aluminium in tea- concentrations, speciation and bioavailability. Coord Chem Rev 2002;228:385-395.
27. Yokel RA, Florence RL. Aluminum bioavailability from tea infusion. Food Chem Toxicol 2008;46:3659-3663.
28. Walton JR. Functional impairment in aged rats chronically exposed to human range dietary aluminum equivalents. Neurotoxicology 2009;30:182-193.
29. Hirota K, Hirota T. Nutrition-related bone disease. Nippon Rinsho 2006;64:1707-1711.
30. Thomas WC, Meyer JL. Aluminum-Induced Osteomalacia: An Explanation. Am J Nephrol 1984;4:201-203.
31. Turner MW, Ardila M, Hutchinson T, Prichard S, Barré PE, Beauvais J, Kaye M. Sporadic aluminum osteomalacia: Identification of patients at risk. Am J Kidney Dis 1988; 11:51-56.
32. Elevated serum aluminum levels in hemodialysis patients associated with use of electric pumps- Wyoming, 2007. MMWR Morb Mortal Wkly Rep 2008;57:689-691.
33. Kaehny WD, Alfrey AC, Holman RE, Shorr WJ. Aluminum transfer during hemodialysis. Kidney Int 1977;12:361-365.
34. Kausz AT, Antonsen JE, Hercz G, Pei Y, Weiss NS, Emerson S, Sherrard DJ. Screening plasma aluminum levels in relation to aluminum bone disease among asymptomatic dialysis patients. Am J Kidney Dis 1999;34: 688-693.
35. Buchman AL, Moukarzel A. Metabolic bone disease associated with total parenteral nutrition. Clin Nutr 2000;19: 217-231.
36. Nomura K, Noguchi Y, Yoshikawa T, Fukuzawa K, Makino T, Tsuburaya A, Imada T, Amano T, Matsumoto A, No-zawa A. Long-term total parenteral nutrition and osteoporosis: Report of a case. Surg Today 1993;23:1027-1031.
37. Jeffery EH, Abreo K, Burgess E, Cannata J, Greger JL. Systemic aluminum toxicity: Effects on bone, hematopoietic tissue, and kidney. J Toxicol Environ Health 1996;48:649-665.
38. Kutlubay R, Oguz EO, Güven C, Can B, Sinik Z, Tuncay OL. Histological and ultrastructural evidence for protective effects on aluminium-induced kidney damage by intra-peritoneal administration of alpha-tocopherol. Int J Toxicol 2007;26:95-101.
39. Mahieu S, Contini Mdel C, González M, Millen N. Mela-tonin reduces oxidative damage induced by aluminium in rat kidney. Toxicol Lett 2009;190:9-15.
40. Mahieu S, Millen N, González M, Contini Mdel C, Eĺas MM. Alterations of the renal function and oxidative stress in renal tissue from rats chronically treated with aluminium during the initial phase of hepatic regeneration. J Inorg Biochem 2005;99:1858-1864.
41. Ecelbarger CA, MacNeil GG, Greger JL. Aluminum retention by aged rats fed aluminum and treated with desfer-rioxamine. Toxicol Lett 1994;73:249-257.
42. Darbre PD. Environmental oestrogens, cosmetics and breast cancer. Best Pract Res Clin Endocrinol Metab 2006;20:121-143.
43. McGrath KG. An earlier age of breast cancer diagnosis related to more frequent use of antiperspirants/deodorants and underarm shaving. Eur J Cancer Prev 2003;12:479-485.
44. Namer M, Luporsi E, Gligorov J, Lokiec F, Spielmann M. The use of deodorants/antiperspirants does not constitute a risk factor for breast cancer. Bull Cancer 2008;95:871-880.
45. Gikas PD, Mansfield L, Mokbel K. Do underarm cosmetics cause breast cancer? Int J Fertil Womens Med 2004;49:212-214.
46. Krewski D, Yokel RA, Nieboer E, Borchelt D, Cohen J, Harry J, Kacew S, Lindsay J, Mahfouz AM, Rondeau V. Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide. J Toxicol Environ Health B Crit Rev 2007;10(Suppl 1):1-269.
47. Hellström HO, Michaëlsson K, Mallmin H, Mjöberg B. The aluminium content of bone, and mortality risk. Age Ageing 2008;37:217-220.
48. Hellström HO, Mjöberg B, Mallmin H, Michaëlsson K. The aluminum content of bone increases with age, but is not higher in hip fracture cases with and without dementia compared to controls. Osteoporos Int 2005;16:1982-1988.
49. Cusack BJ. Pharmacokinetics in older persons. Am J Geriatr Pharmacother 2004;2:274-302.
50. Mühlberg W, Platt D. Age-dependent changes of the kidneys: Pharmacological implications. Gerontology 1999;45: 243-253.
51. Exley C, Burgess E, Day JP, Jeffery EH, Melethil S, Yokel RA. Aluminum toxicokinetics. J Toxicol Environ Health 1996;48:569-584.
52. Yokel RA, McNamara PJ. Aluminium toxicokinetics: An updated minireview. Pharmacol Toxicol. 2001;88:159-167.
53. Sahin G, Varol I, Temizer A, Benli K, Demirdamar R, Duru S. Determination of aluminum levels in the kidney, liver, and brain of mice treated with aluminum hydroxide. Biol Trace Elem Res 1994;41:129-135.
54. Turner MW, Ardila M, Hutchinson T, Prichard S, Barré PE, Beauvais J, Kaye M. Sporadic aluminum osteomalacia: Identification of patients at risk. Am J Kidney Dis 1988;11: 51-56.
55. McLachlan DR, Bergeron C, Smith JE, Boomer D, Rifat SL. Risk for neuropathologically confirmed Alzheimer's disease and residual aluminum in municipal drinking water employing weighted residential histories. Neurology 1996:46:401-405.
56. Levallois P. Alzheimer's disease and aluminum. Neurology 1997;48:1141-1142.
57. Kaneko N, Yasui H, Takada J, Suzuki K, Sakurai H. Orally administrated aluminum-maltolate complex enhances oxi-dative stress in the organs of mice. J Inorg Biochem 2004;98:2022-2031.
58. Bharathi NM, Shamasundar TS, Sathyanarayana Rao M, Dhanunjaya Naidu R, Ravid KS, J Rao. A new insight on Al-maltolate-treated aged rabbit as Alzheimer's animal model. Brain Res Rev 2006;52:275-292.
59. Domingo JL. Aluminum and other metals in Alzheimer's disease: A review of potential therapy with chelating agents. J Alzheimers Dis 2006;10:331-341.
60. Yokel RA, Hicks CL, Florence RL. Aluminum bioavail-ability from basic sodium aluminum phosphate, an approved food additive emulsifying agent, incorporated in cheese. Food Chem Toxicol 2008;46:2261-2266.
61. Street R, Drabek O, Szakova J, Mladkova, L. Total content and speciation of aluminium in tea leaves and tea infusions. Food Chem 2007;104:1662-1669.
62. Ishiwata, H. Aluminum levels in food-simulating solvents and various foods cooked in aluminum pans. J Agric Food Chem 1988;36:599-601.
63. Jouhanneau P, Raisbeck GM, Yiou F, Lacour B, Banide H, Drü eke TB. Gastrointestinal absorption, tissue retention, and urinary excretion of dietary aluminum in rats determined by using 26Al. Clin Chem 1997;43(6 Pt 1):1023-1028.
64. Flarend R, Bin T, Elmore D, Hem SL. A preliminary study of the dermal absorption of Al from antiperspirants using Al-26. Food Chem Toxicol 2003;39:163-168.
65. Guillard O, Fauconneau B, Olichon D, Dedieu G, Deloncle R. Hyperaluminemia in a woman using an aluminium-containing antiperspirant for 4 years. Am J Med 2004;117: 956-959.
66. Moshtaghie AA, Ani M, Bazrafshan MR. Comparative binding study of aluminum and chromium to human trans-ferrin. Effect of iron. Biol Trace Elem Res 1992;32:39-46.
67. Fatemi SJ, Kadir FH, Moore GR. Aluminium transport in blood serum. Binding of aluminium by human transferrin in the presence of human albumin and citrate. Biochem J 1991;280(Pt 2):527-532.
68. Bogdanović M, Bulat P. Biliary function in workers occu-pationally exposed to aluminium dust and fumes. Arh Hig Rada Toksikol 2008;59:135-139.
69. Blanusa M, Varnai VM, Piasek M, Kostial K. Chelators as antidotes of metal toxicity: Therapeutic and experimental aspects. Curr Med Chem 2005;12:2771-2794.
70. Ricchelli F, Drago D, Filippi B, Tognon G, Zatta P. Aluminum-triggered structural modifications and aggregation of beta-amyloids. Cell Mol Life Sci 2005;62:1724-1733.
71. Kruck TP, Cui JG, Percy ME, Lukiw WJ. Molecular shuttle chelation: The use of ascorbate, desferrioxamine and Fer-alex-G in combination to remove nuclear bound aluminum. Cell Mol Neurobiol 2004;24:443-459.
72. Felsenfield AJ, Rodriguez M, Coleman M, Ross D, Llach F. Desferrioxamine therapy in hemodialysis patients with aluminum-associated bone disease. Kidney Int 1989;35: 1371-1378.
73. De Broe ME, D'Haese PC, Couttenye MM, Van Landeghem GF, Lamberts LV. New insights and strategies in the diagnosis and treatment of aluminium overload in dialysis patients. Nephrol Dial Transplant 1993;8(Suppl 1):47-50.
74. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89:739-761.
75. Flora SJ, Mehta A, Satsangi K, Kannan GM, Gupta M. Aluminum-induced oxidative stress in rat brain: response to combined administration of citric acid and HEDTA. Comp Biochem Physiol C Toxicol Pharmacol 2003;134: 319-328.
76. Symons M, Gutteridge, J. Free Radicals and Iron: Chemistry, Biology, and Medicine. Oxford University Press, Oxford, 1998.
77. Zatta P, Drago D, Bolognin S, Sensi SL. Alzheimer's disease, metal ions and metal homeostatic therapy. Trends Pharmacol Sci 2009;30:346-355.
78. Kell DB. Iron behaving badly: Inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics 2009;2:2.
79. Mascitelli L, Pezzetta F, Goldstein MR. Iron, type 2 diabetes mellitus, and Alzheimer's disease. Cell Mol Life Sci 2009;66:2943; author reply 2945; discussion 2947.
80. Exley C. Aluminium and iron, but neither copper nor zinc, are key to the precipitation of beta-sheets of Abeta-{42} in senile plaque cores in Alzheimer's disease. J Alzheimers Dis 2006;10:173-177.
81. Yamamoto A, Shin RW, Hasegawa K, Naiki H, Sato H, Yoshimasu F, Kitamoto T. Iron (III) induces aggregation of hyperphosphorylated tau and its reduction to iron (II) reverses the aggregation: Implications in the formation of neurofibrillary tangles of Alzheimer's disease. J Neurochem 2002;82:1137-1147.
82. Jiang D, Li X, Williams R, Patel S, Men L, Wang Y, Zhou F. Ternary complexes of iron, amyloid-beta, and nitrilo-triacetic acid: Binding affinities, redox properties, and relevance to iron-induced oxidative stress in Alzheimer's disease. Biochemistry 2009;48:7939-7947.
83. Bush AI, Tanzi RE. Therapeutics for Alzheimer's disease based on the metal hypothesis. Neurotherapeutics 2008;5:421-432.
84. Zacharski LR, Chow BK, Howes PS, Shamayeva G, Baron JA, Dalman RL, Malenka DJ, Ozaki CK, Lavori PW. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: Results from a randomized trial. J Natl Cancer Inst 2008;100:996-1002.
85. Akiba S, Neriishi K, Blot WJ, Kabuto M, Stevens RG, Kato H, Land CE. Serum ferritin and stomach cancer risk among a Japanese population. Cancer 1991;67:1707-1712.
86. Fracanzani AL, Conte D, Fraquelli M, Taioli E, Mattioli M, Losco A, Fargion S. Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology 2001;33:647-651. http://diabetes.webmd.com/ guide/default.htm. Accessed November 28, 2008.
87. Hua NW, Stoohs RA, Facchini FS. Low iron status and enhanced insulin sensitivity in lacto-ovo vegetarians. Br J Nutr 2001;86:515-519.
88. Zheng H, Patel M, Cable R, Young L, Katz SD. Insulin sensitivity, vascular function, and iron stores in voluntary blood donors. Diabetes Care 2007;30:2685-2689.
89. Braughler JM, Duncan LA, Chase RL. The involvement of iron in lipid peroxidation. Importance of ferric to ferrous ratios in initiation. J Biol Chem 1986;261:10282-10289.
90. Armutcu F, Gurel A, Aker A. Serum iron concentrations, lipid peroxidation and superoxide dismutase activity in Turkish iron miners. Environ Geochem Health 2004;26: 1-4.
91. King SM, Donangelo CM, Knutson MD, Walter PB, Ames BN, Viteri FE, King JC. Daily supplementation with iron increases lipid peroxidation in young women with low iron stores. Exp Biol Med (Maywood) 2008;233:701-707.
92. Livrea MA, Tesoriere L, Maggio A, D'Arpa D, Pintaudi AM, Pedone E. Oxidative modification of low-density li-poprotein and atherogenetic risk in beta-thalassemia. Blood 1998;92:3936-3942.
93. Verhoye E, Langlois MR; Asklepios Investigators. Collaborators: Rietzchel E, De Buyzere M, Gillebert T, De Bac-quer D, De Backer G, Bekaert S, van Oostveldt P, Segers P, Verdonck P, Langlois M. Circulating oxidized low-density lipoprotein: A biomarker of atherosclerosis and cardiovascular risk? Clin Chem Lab Med 2009;47:128-137.
94. Leitinger N. Oxidized phospholipids as triggers of inflammation in atherosclerosis. Mol Nutr Food Res 2005;49:1063-1071.
95. Zegrean M. Association of body iron stores with development of cardiovascular disease in the adult population: A systematic review of the literature. Can J Cardiovasc Nurs 2009;19:26-32.
96. Altamura S, Muckenthaler MU. Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis. J Alzheimers Dis 2009;16:879-895.
97. Crichton RR, Wilmet S, Legssyer R, Ward RJ. Molecular and cellular mechanisms of iron homeostasis and toxicity in mammalian cells. J Inorg Biochem 2002;91:9-18.
98. Oshiro S, Kawamura K, Zhang C, Sone T, Morioka MS, Kobayashi S, Nakajima K. Microglia and astroglia prevent oxidative stress-induced neuronal cell death: Implications for aceruloplasminemia. Biochim Biophys Acta 2008;1782: 109-117.
99. Maynard CJ, Cappai R, Volitakis I, Cherny RA, White AR, Beyreuther K, Masters CL, Bush AI, Li QX. Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. J Biol Chem 2002;277:44670-44676.
100. Schipper HM. Chapter 123. Metal accumulation during aging. Encyclopedia of Neuroscience. Squire LR, ed. Oxford: Academic Press, pp 811-818, 2009.
101. Xu J, Knutson MD, Carter CS, Leeuwenburgh C. Iron accumulation with age, oxidative stress and functional decline. PLoS One 2008;3:e2865.
102. Chen H, Lukas TJ, Du N, Suyeoka G, Neufeld AH. Dysfunction of the retinal pigment epithelium with age: increased iron decreases phagocytosis and lysosomal activity. Invest Ophthalmol Vis Sci 2009;50:1895-1902.
103. Cook CI, Yu BP. Iron accumulation in aging: modulation by dietary restriction. Mech Ageing Dev 1998;102:1-13.
104. Borten O, Liberman A, Tuchweber B, Chevalier S, Ferland G, Schipper HM. Effects of dietary restriction and metal supplementation on the accumulation of iron-laden glial inclusions in the aging rat hippocampus. Biogerontology 2004;5:81-88.
105. Guyatt GH, Patterson C, Ali M, Singer J, Levine M, Turpie I, Meyer R. Diagnosis of iron-deficiency anemia in the elderly. Am J Med 1990;88:205-209.
106. Gersten, T, Zieve, D. Ferritin [Internet]. Bethesda, MD. Jan. 12, 2009 [updated Sept. 21, 2009; cited Oct.14, 2009]. Available from http://www.nlm.nih.gov/medlineplus/ency/article/003490.htm/.
107. Zacharski LR, Chow BK, Howes PS, Lavori PW, Sha-mayeva G. Implementation of an iron reduction protocol in patients with peripheral vascular disease: VA cooperative study no. 410: The Iron (Fe) and Atherosclerosis Study (FeAST). Am Heart J 2004;148:386-392.
108. Hallberg L, Hultén L, Gramatkovski E. Iron absorption from the whole diet in men: how effective is the regulation of iron absorption? Am J Clin Nutr 1997;66:347-356
109. Knovich MA, Storey JA, Coffman LG, Torti SV, Torti FM. Ferritin for the clinician. Blood Rev 2009;23:95-104.
110. Ponka, P. Iron metabolism: physiology and pathophysi-ology. J Trace Elements Exp Med 2000;13:73-83.
111. Sumida Y, Kanemasa K, Fukumoto K, Yoshida N, Sakai K. Effects of dietary iron reduction versus phlebotomy in patients with chronic hepatitis C: Results from a randomized, controlled trial on 40 Japanese patients. Intern Med 2007;46:637-642.
112. Lee TS, Shiao MS, Pan CC, Chau LY. Iron-deficient diet reduces atherosclerotic lesions in apoE-deficient mice. Circulation 1999;99:1222-1229.
113. Anderson GJ, Frazer DM, McKie AT, Vulpe CD, Smith A. Mechanisms of haem and non-haem iron absorption: Lessons from inherited disorders of iron metabolism. Biome-tals 2005;18:339-348.
114. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. Article on iron deficiency [Internet]. Atlanta (GA): Centers for Disease Control and Prevention; [updated May 22, 2007]. Iron deficiency; [updated May 22, 2007; cited Nov. 28, 008]. Available from http://www.cdc.gov/ nccdphp/dnpa/nutrition/nutrition-everyone/iron-deficiency/index.htm/.
115. Brune M, Rossander-Hultén L, Hallberg L, Gleerup A, Sandberg AS. Iron absorption from bread in humans: Inhibiting effects of cereal fiber, phytate and inositol phosphates with different numbers of phosphate groups. J Nutr 1992;122:442-449.
116. Sandberg AS, Brune M, Carlsson NG, Hallberg L, Skoglund E, Rossander-Hulthén L. Inositol phosphates with different numbers of phosphate groups influence iron absorption in humans. Am J Clin Nutr 1999;70:240-246.
117. Harland B, Morris E. Phytate a good or bad food component? Nutr Res 1995;15:733-754.
118. Gillooly M, Bothwell TH, Charlton RW, Torrance JD, Bez-woda WR, MacPhail AP, Derman DP, Novelli L, Morrall P, Mayet F. Factors affecting the absorption of iron from cereals. Br J Nutr 1984;51:37-46.
119. Geerligs PD, Brabin BJ, Omari AA. Food prepared in iron cooking pots as an intervention for reducing iron deficiency anaemia in developing countries: A systematic review. J Hum Nutr Diet 2003;16:275-281.
120. Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: New data, new questions. Blood 2006;107:3436-3441.
121. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. Article on hemo-chromatosis treatment. Atlanta (GA): Centers for Disease Control and Prevention; [updated Jun 6, 2009]. Iron overload and hemochromatosis: Treatment; [updated May 22, 2007; cited Nov 3, 2009]. Available from: http://www .cdc.gov/ncbddd/hemochromatosis/treatment.htm.